Commodore Capital LP Cardiff Oncology, Inc. Call Options Transaction History
Commodore Capital LP
- $998 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRDF
# of Institutions
114Shares Held
16.2MCall Options Held
694KPut Options Held
140K-
Black Rock Inc. New York, NY2.63MShares$11.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$9.8 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.54MShares$6.6 Million0.18% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$6.19 Million3.38% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.29MShares$5.54 Million0.01% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $186M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...